Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Deloitte
Boehringer Ingelheim
Cerilliant
Medtronic
Farmers Insurance
UBS
McKinsey
Fish and Richardson
Express Scripts

Generated: October 18, 2017

DrugPatentWatch Database Preview

CRIXIVAN Drug Profile

« Back to Dashboard

Which patents cover Crixivan, and what generic Crixivan alternatives are available?

Crixivan is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this drug.

This drug has forty-two patent family members in thirty-five countries.

The generic ingredient in CRIXIVAN is indinavir sulfate. There are two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the indinavir sulfate profile page.

Summary for Tradename: CRIXIVAN

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list5
Bulk Api Vendors: see list74
Clinical Trials: see list11
Patent Applications: see list2,304
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CRIXIVAN at DailyMed

Pharmacology for Tradename: CRIXIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-006Apr 19, 2000DISCNNoNo► Subscribe► Subscribe ► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-001Mar 13, 1996RXYesYes► Subscribe► Subscribe ► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-003Mar 13, 1996RXYesNo► Subscribe► SubscribeY ► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-001Mar 13, 1996RXYesYes► Subscribe► SubscribeY ► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-006Apr 19, 2000DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-003Mar 13, 1996RXYesNo► Subscribe► Subscribe ► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-005Dec 17, 1998DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-005Dec 17, 1998DISCNNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CRIXIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-005Dec 17, 1998► Subscribe► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-006Apr 19, 2000► Subscribe► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-003Mar 13, 1996► Subscribe► Subscribe
Merck Sharp Dohme
CRIXIVAN
indinavir sulfate
CAPSULE;ORAL020685-001Mar 13, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: CRIXIVAN

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe
CRIXIVAN
► Subscribe

International Patent Family for Tradename: CRIXIVAN

Country Document Number Estimated Expiration
Peru38397► Subscribe
Czech Republic9702444► Subscribe
China1179722► Subscribe
Mexico9705916► Subscribe
Eurasian Patent Organization000437► Subscribe
New Zealand302153► Subscribe
Estonia9700165► Subscribe
Portugal806957► Subscribe
Spain2200052► Subscribe
Yugoslavia49417► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cipla
McKesson
Julphar
QuintilesIMS
US Department of Justice
Chinese Patent Office
Boehringer Ingelheim
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot